Stamford-based medical device company Neuvotion, Inc. is launching NeuStim™, an FDA-cleared device that delivers non-invasive electrical stimulation to muscles to support recovery after stroke and spinal cord injury, as part of a broader AI-guided brain-body interface platform.

NeuStim™ is designed to help clinicians quickly identify and target stimulation points through a touch-screen interface that allows electronic adjustment of the stimulation location, eliminating the need for manual electrode removal and replacement. Stimulation profiles can be saved for individual patients through a graphical user interface on a lightweight mobile device. The company expects the product to launch later this year.

Neuvotion is also developing FocalStim™, a product aimed at precise spinal cord stimulation to improve and accelerate movement recovery outcomes, with an expected introduction next year. The company has additionally entered the brain-computer interface market with minimally-invasive technology under development, working toward a full brain-body interface system intended to restore both movement and sensation.

Dr. Chad Bouton, Neuvotion's founder and CEO, said, "At Neuvotion we are extremely excited to help create new markets and applications for brain-computer interface and brain-body interface technologies. We are also thrilled about launching NeuStim™ later this year, and our FocalStim™ product that is under development and will be introduced next year."

Neuvotion develops technologies combining high-precision neurostimulation and artificial intelligence to improve and accelerate rehabilitation, with the goal of making physical and occupational therapy more effective and efficient for patients experiencing impairment from stroke, spinal cord injury, and other neurological conditions.